
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
BIOREGNUM — the view from John Carroll
With the price of drugs front and center in Washington DC these days, Regeneron and Sanofi are attracting kudos for their decision to hold back the price hike on Dupixent to a mere 3%, which the pharma giant notes is well within the rate of medical inflation — their cap on price increases.
Both of these companies went through the ringer on PCSK9 pricing — which have come down — and Regeneron CEO Len Schleifer has been a consistent counsel for avoiding the big annual price increases that is attracting so much criticism these days.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.